915156-10-4

Upstream product

• 915156-09-1 2-amino-3-bromo-5-nitro-phenol 
• 75-30-9 2-iodo-propane 
• 116632-23-6 3-bromo-5-nitro-phenol 

Downstream Products

• 1251863-18-9 1-{3-isopropoxy-5-[7-(4-methylimidazol-1-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1251863-16-7 1-{3-isopropoxy-5-[7-(5-methyl[1,3,4]oxadiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoro-1-hydroxyethyl)urea 
• 1251863-15-6 {3-isopropoxy-5-[7-(5-methyl[1,3,4]oxadiazol-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}urea 
• 1251863-14-5 1-{3-isopropoxy-5-[7-(4-isopropylpyrimidin-2-yl)imidazo[1,2-a]pyridin-3-yl]phenyl}-3-(2,2,2-trifluoroethyl)urea 
• 1251863-13-4 1-(3-{7-[4-(2-hydroxy-1,1-dimethylethyl)pyrimidin-2-yl]imidazo[1,2-a]pyridin-3-yl}-5-isopropoxyphenyl)-3-(2,2,2-trifluoroethyl)urea 
• 1251863-12-3 2-[2-(3-{3-isopropoxy-5-[3-(2,2,2-trifluoroethyl)ureido]phenyl}imidazo[1,2-a]pyridin-7-yl)pyrimidin-4-yl]-2-methylpropionic acid ethyl ester 
• 1251863-08-7 1-[3-isopropoxy-5-(7-[1,3,4]thiadiazol-2-ylimidazo[1,2-a]pyridin-3-yl)phenyl]-3-(2,2,2-trifluoroethyl)urea 
• 1251863-83-8 C₁₉H₁₉N₅O₂ 
• 1251863-82-7 C₁₉H₂₀BF₃N₄O₄ 
• 1251863-81-6 C₁₉H₁₈ClF₃N₄O₂ 
• 1251863-67-8 C₂₆H₃₁F₃N₄O₅ 
• 1251863-09-8 1-{3-[7-(2-Hydroxy-ethoxy)-imidazo[1,2-a]pyridin-3-yl]-5-isopropoxy-phenyl}-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251863-06-5 1-{3-Isopropoxy-5-[7-(5-methyl-[1,3,4]oxadiazol-2-yl)-imidazo[1,2-a]pyridin-3-yl]-phenyl}-3-(2,2,2-trifluoro-ethyl)-urea 
• 1251863-05-4 1-[3-Isopropoxy-5-(7-pyrimidin-2-yl-imidazo[1,2-a]pyridin-3-yl)-phenyl]-3-(2,2,2-trifluoro-ethyl)-urea 

Relevant academic research and scientific papers

Receptor-interacting protein kinase 2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling inhibitors based on a 3,5-diphenyl-2-aminopyridine scaffold

Receptor-interacting protein kinase 2 (RIPK2) is a key mediator of nucleotide-binding oligomerization domain (NOD) cell signaling that has been implicated in various chronic inflammatory conditions. A new class of RIPK2 kinase/NOD signaling inhibitors bas

MACROCYCLIC RIP2-KINASE INHIBITORS

The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2-kinase, and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.

BICYCLIC HETEROCYCLYL DERIVATIVES AS FGFR KINASE INHIBITORS FOR THERAPEUTIC USE

The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

IMIDAZO [1,2-A]PYRIDINE DERIVATIVES AS FGFR KINASE INHIBITORS FOR USE IN THERAPY

The invention relates to new bicyclic heterocyclyl derivatives of formula (I), to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

INHIBITORS OF MATRIX METALLOPROTEINASES

The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.